Breaking News

SK bioscience to Establish a Vaccine-Biopharma Hub

The R&PD Center will be a 30,413.8㎡ site in Songdo, Republic of Korea with a total investment of $261 million.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

SK bioscience, a global innovative vaccine and biotech company, plans to initiate the establishment of the ‘Songdo Global Research & Process Development Center (The R&PD Center).’   The R&PD Center will be a 30,413.8㎡ site in Songdo, Republic of Korea with a total investment of $261 million, including the previous investment of $33 million.   Once the R&PD Center is completed in the first half of 2025, the headquarters and the research and development (R&D) ce...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters